Abstract: Pharmaceutical compositions comprising reboxetine or a pharmaceutically acceptable salt thereof and a muscarinic receptor antagonist (MRA) and methods of treating sleep apnea comprising administering reboxetine or a pharmaceutically acceptable salt thereof and an MRA are described herein. In some embodiments, the MRA is oxybutynin or (R)-oxybutynin or a pharmaceutically acceptable salt thereof.

Abstract: Pharmaceutical compositions comprising Lemborexant or a pharmaceutically acceptable salt thereof and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering Lemborexant or a pharmaceutically acceptable salt thereof and an NRI are described herein. In some embodiments, the NRI is atomoxetine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions further comprise a muscarinic receptor antagonist (MRA). In some embodiments, the methods of treating Sleep Apnea further comprise administering an MRA. In some embodiments, the MRA is oxybutynin or a pharmaceutically acceptable salt thereof.

Abstract: In general, the invention relates to pharmaceutical compositions comprising a thyrotropin-releasing hormone (TRH) analog, and methods of treating sleep apnea comprising administering a TRH analog.

Abstract: In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.

Abstract: In general, the invention relates to pharmaceutical compositions comprising 4-hydroxyatomoxetine used with a muscarinic receptor antagonist, and methods of treating sleep apnea comprising administering a muscarinic receptor antagonist and 4-hydroxyatomoxetine. The 4-hydroxyatomoxetine and muscarinic receptor antagonist are disposed in a pharmaceutically acceptable carrier.